InterventionsHumans

Paxlovid Use for SARS-CoV-2 Infection and Two-Year Risk of Diabetes: The COVID-19 and Diabetes Assessment (CODA) Study

ADA Scientific Sessions 2026 Abstract

The paper

Bahareh Rasouli, S. L. Rifas‐Shiman, Jessica G. Young,

Thomas Eggerman, Benjamin French, Marie-France Hivert, Sean Mcgrath, Alvin C. Powers, Jennifer G. Lyons, Russell L. Rothman, Jonathan S. Schildcrout,

Bethesda

ADA Scientific Sessions 2026 Abstract · 6 Jun 2026

Presented at ADA Scientific Sessions 2026 · Oral 1163-OR

doi.org/10.2337/db26-1163-or

COVID-19 tied to higher dementia risk in older adults with diabetes
Frontiers in Aging Neuroscience · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism · 8 Oct 2026